Articles related to METABOLIC HEALTH

A 2025 AACE consensus statement introduced a complication-centric, staged framework for managing adults with obesity and adiposity-based chronic disease, with drug selection tied to specific obesity-related complications rather than weight loss alone.

A 14-year international consensus effort involving 56 professional and patient organizations has renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome, a shift designed to better reflect the condition’s systemic hormonal and metabolic pathophysiology.

Bariatric surgery volumes peaked in 2022 and have fallen since, with sleeve gastrectomy losing ground and Roux-en-Y conversions climbing as GLP-1 prescriptions expand.

A systematic review of 27 studies found behavioral sleep interventions — particularly CBT-I and sleep hygiene — reduced BMI and body weight in adults with poor sleep health, with the largest effects among patients with obesity.

Retrospective analyses presented at SABCS 2025 associated GLP-1 receptor agonist use with weight loss, mortality, and recurrence signals in breast cancer cohorts, with effects on endocrine therapy tolerability also observed.

Boehringer Ingelheim’s SYNCHRONIZE-1 phase 3 trial reported 16.6% average body weight reduction with survodutide, a dual GLP-1/glucagon receptor agonist, over 76 weeks in adults without type 2 diabetes.